SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): October 6, 2009
TRANSDEL PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
| |
|
|
|
|
Delaware
(State of Incorporation)
|
|
000-52998
(Commission File Number)
|
|
45-0567010
(I.R.S. Employer Identification No.) |
| |
|
|
4225 Executive Square, Suite 485, La Jolla, California
(Address of Principal Executive Offices)
|
|
92037
(Zip Code) |
Registrant’s telephone number, including area code: (858) 457-5300
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 8.01 Other Events.
In connection with the announcement by Transdel Pharmaceuticals, Inc. (the “Company”) of the
top-line results of the Phase 3 clinical study of Ketotransdel®, the Company issued a press release
on October 6, 2009. A copy of this press release is included as Exhibit 99.1 to this Current Report
on Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits
| |
|
|
| Exhibit No. |
|
Description |
|
|
|
99.1
|
|
Press Release of the Company, dated October 6, 2009. |